Research programme: hepatitis C virus therapies - Kemin Pharma
Alternative Names: KPE-00001113Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
- Class Carbohydrates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in Belgium
- 15 Jan 2004 Preclinical trials in Hepatitis C treatment in Belgium (unspecified route)